Cubist Pharmaceuticals developed and commercialized CUBICIN® (daptomycin for injection), which has experienced the most successful IV antibiotic launch, in dollar terms, in U.S. history. In the U.S., Cubist also promotes Merrem I.V., an established broad spectrum carbapenem antibiotic, for AstraZeneca. As we continue to optimize CUBICIN and look for opportunities beyond Merrem I.V. to leverage the expertise of our U.S. hospital commercial organization, we also are developing several promising compounds in our clinical and pre-clinical pipeline.
Cubist believes CUBICIN will continue growing (to greater than $1 Billion annually in the U.S. alone) with its current labeled indications and has not yet made decisions on the appropriateness of additional registration (Phase 3) studies.
The company has a growing clinical and pre-clinical pipeline of programs which can leverage Cubist's scientific, clinical and regulatory expertise as well as its proven acute care commercial organization.
Learn more about Ecallantide, in development as therapy to reduce bleeding in on-pump cardiac surgery
Learn more about CB-183,315, in development for Clostridium difficile infections
Learn more about CB-182,804 in development for infections caused by Gram-negative bacteria